Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

Meletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, Sosana Delimpasi, Meral Beksaç, Eirini Katodritou, Philippe Moreau, Luca Baldini, Argiris Symeonidis, Jelena Bila, Albert Oriol, María‐Victoria Mateos, Hermann Einsele, Ioannis Orfanidis, Tahamtan Ahmadi, Jon Ukropec, Tobias Kampfenkel, Jordan M. Schecter, Yanping Qiu, Himal Amin, Jessica Vermeulen, Robin Carson, Pieter Sonneveld, Adrián Alegre Amor, Luca Baldini, Meral Beksaç, Angelo Belotti, Lotfi Benboubker, Britta Besemer, Sevgi Kalayoğlu Beşışık, Jelena Bila, Mario Boccadoro, Michèle Cavo, Javier de la Rubia Comos, Sosana Delimpasi, Meletios A Dimopoulos, Chantal Doyen, Dominik Dytfeld, Monika Engelhardt, Thierry Façon, Roberto Foà, Hartmut Goldschmidt, Sebastian Grosicki, Roman Hájek, Güner Hayri Özsan, Cyrille Hulin, Brian Iversen, Lionel Karlin, Eirini Katodritou, Stefan Knop, Marie‐Christine Kyrtsonis, Juan José Lahuerta, Xavier Leleu, Carmen Martínez Chamorro, María-Victoria Mateos Manteca, Nathalie Meuleman, Monique C. Minnema, Philippe Moreau, Massino Offidani, Albert Oriol Rocafiguera, Mustafa Pehlıvan, Luděk Pour, Henk Roerdink, Laura Rosinol Dacsh, Hans Salwender, Pieter Sonneveld, Argiris Symeonidis, Charlotte Toftmann Hansen, Tülin Tuğlular, Ali Ünal, Philip Vlummens, Filiz Vural, Ka Lung Wu, Sonja Zweegman (2021). Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. , 22(6), DOI: https://doi.org/10.1016/s1470-2045(21)00128-5.